5 Best Peptides for Hypoactive Sexual Desire Disorder (HSDD)

What to Know Before Choosing a Peptide for HSDD

Hypoactive Sexual Desire Disorder is defined by a persistent, distressing absence of sexual desire, not just a low-libido stretch or a rough patch. It affects both women and men, though most of the formal research has focused on premenopausal women. The field of peptides relevant to HSDD is small but surprisingly well-developed at the clinical end and genuinely active at the investigational end, which means the list here reflects a real spread of options rather than one obvious answer padded with filler.

A compound earned a slot on this list because people use it or are actively discussing using it for HSDD. That is the whole test. FDA-approved, telemedicine-prescribed, and research-only compounds are all eligible. Evidence strength is stated honestly inside each entry and is never used as a filter for inclusion. One compound here has Phase 3 randomized controlled trial data and a formal FDA approval. Others have Phase 2 data from reputable institutions. One is primarily an adjunct with a mixed evidence base. One sits mostly in community-discussed territory with meaningful caveats. All of them belong because all of them show up when people are genuinely searching this goal.

The entries are numbered by how prominently each compound appears in research and documented real-world use for HSDD, not as a ranking of one compound being better than another for any individual person. Number one is the most clinically established option for this specific condition. That does not make it the right choice for everyone reading this. Your hormonal status, cardiovascular history, whether your low desire is primarily neurochemical or hormonal, and a number of other factors all shape the decision. The numbers give the list a logical shape. They are not a verdict.

1. PT-141 (Bremelanotide): The Only FDA-Approved Peptide for HSDD

PT-141, sold under the brand name Vyleesi, is the compound that anchors this entire field. It is the only peptide the FDA has approved specifically for HSDD, receiving that approval in June 2019, and it remains the reference point when people talk about peptide-based approaches to low sexual desire.

Chemically, PT-141 is a cyclic heptapeptide, a small ring-shaped protein structure, derived originally from Melanotan II but modified to improve receptor selectivity. Its primary target is the melanocortin-4 receptor (MC4R), a receptor found on neurons in brain regions involved in motivation, reward, and desire. When PT-141 activates these receptors, it triggers dopamine release across circuits in the hypothalamus, the nucleus accumbens, and the amygdala. The result is an increase in what researchers describe as anticipatory sexual desire, the part of wanting sex that initiates in the mind before any physical stimulation begins. This is what makes PT-141 mechanistically distinct from compounds like sildenafil or tadalafil, which work peripherally by increasing blood flow to genital tissue. PT-141 targets the brain's own desire-generating system directly.

The pivotal evidence comes from the two RECONNECT Phase 3 trials, a pair of randomized, double-blind, placebo-controlled studies involving 1,247 premenopausal women diagnosed with HSDD. Both trials met their co-primary endpoints. Women using PT-141 showed statistically significant improvements in desire scores on a validated sexual function scale and statistically significant reductions in distress compared to placebo. In one of the trials, PT-141 users reported approximately one additional satisfying sexual event per month compared to roughly 0.4 in the placebo group. About 34 percent of PT-141 users achieved a clinically meaningful improvement in desire, compared to roughly 23 percent on placebo. The effect size is modest, and a 2023 meta-analysis noted that the benefits were statistically real but not dramatic. Even so, the FDA considered them meaningful enough to approve the compound as the first peptide treatment for this condition, and a 52-week open-label extension found that benefits held over time with no new safety signals emerging.

The FDA approval covers acquired, generalized HSDD in premenopausal women specifically. Use in postmenopausal women and in men is off-label. Phase 2 trials studying PT-141 in men who had not responded to PDE5 inhibitors were underway as of 2025, but no FDA approval for men exists as of 2026. Off-label and compounded versions are prescribed through some telehealth platforms for these populations.

The safety profile is well-characterized from the trial data. Nausea is the most common side effect, affecting roughly 40 percent of users in clinical studies. Facial flushing occurs in about 20 percent and headache in about 12 percent. There is a transient increase in blood pressure of up to six points systolic and a corresponding small decrease in heart rate; these effects are temporary but clinically significant for people with uncontrolled hypertension or known cardiovascular disease, both of which are boxed warning contraindications. A small number of users experience hyperpigmentation, darkening of the skin on the face, gums, or breasts, at roughly one percent at maximum doses, driven by the melanocortin system's effect on melanin-producing cells. PT-141 can also slow gastric emptying, which may affect how quickly oral medications taken at the same time are absorbed. Across community reports, nausea tends to be described as dose-dependent, and users who begin at a lower amount and titrate up report it less often.

PT-141 circulates in two distinct forms: the FDA-approved Vyleesi product dispensed through specialty pharmacies with a prescription, and compounded or research-chemical versions available through other channels. The FDA has explicitly stated that many non-Vyleesi formulations lack clinical validation and quality control. The regulatory and safety gap between the two forms is real and worth understanding before pursuing either.

2. Kisspeptin-10: For Hormonally Driven Low Desire

Kisspeptin-10 occupies a genuinely interesting position in this field. It has real human clinical trial data published in a peer-reviewed journal, it works through a completely different pathway than PT-141, and it remains investigational with no commercial approval for sexual health indications as of 2026. That combination makes it one of the more scientifically credible options people are actively discussing for HSDD without yet being able to access through standard prescribing channels.

Kisspeptin is a naturally occurring neuropeptide that acts as a master regulator of the hypothalamic-pituitary-gonadal (HPG) axis, the hormonal chain running from brain signals through the pituitary gland to the gonads that governs sex hormone production. Think of it as the upstream switch that tells the whole hormonal cascade when to activate. Kisspeptin-10 is the active fragment of this peptide. By binding to its receptor, GPR54, it stimulates the upstream release of gonadotropin-releasing hormone, which in turn drives luteinizing hormone and follicle-stimulating hormone release, influencing testosterone and estrogen production downstream. Where PT-141 fires the desire signal directly through the brain's dopamine reward circuitry on demand, Kisspeptin-10 works by restoring the hormonal signaling that feeds into desire over a longer arc. These are different tools for what may sometimes be the same complaint.

The most important clinical data comes from a 2023 randomized trial conducted at Imperial College London and published in JAMA Network Open. The study enrolled 64 participants with HSDD, 32 men and 32 women. In men, Kisspeptin-10 produced a 56 percent increase in penile tumescence compared to placebo and improved behavioral desire scores, both reaching statistical significance. Brain imaging showed modulation of sexual-processing networks with an effect size (Cohen's d) of 0.81, which is considered large in behavioral research. In women, the compound reduced activity in brain regions linked to negative self-evaluation and body image while increasing activity in emotional processing areas, a pattern the researchers considered relevant to the psychological dimension of HSDD. The Imperial College team described these as the first clinical studies demonstrating that kisspeptin can boost sexual pathways in this population. No Phase 3 trial data has been published as of 2026.

Community discussion of Kisspeptin-10 tends to frame it as a promising option for people who suspect their low desire has a hormonal rather than a purely neurochemical root, or for those exploring alternatives to PT-141's injectable model. The personal accounts are genuinely sparse compared to PT-141, mostly reflecting the compound's investigational status and limited availability. The honest picture is that the Phase 2 data is encouraging and the mechanism is coherent, but widespread real-world experience in HSDD has not accumulated the way it has for the only FDA-approved option.

As of 2026, Kisspeptin-10 is available only as a research compound. There is no telemedicine prescribing pathway for an HSDD indication, no standardized clinical dosing protocol established outside of research settings, and no FDA-approved product for this use.

3. Orenetide (BP-101): The Investigational Nasal Spray for Women

Orenetide, referred to in earlier development stages as BP-101 and marketed under the investigational name Desirix, is a peptide developed specifically to treat HSDD in women. It is not FDA-approved as of 2026, but it has completed Phase 2 trials with positive results, making it the most advanced investigational peptide designed specifically for this condition after PT-141.

The most practically notable feature of Orenetide is its delivery route. It is administered as an intranasal spray rather than by subcutaneous injection, which matters for people who find the injectable nature of PT-141 to be a barrier. Whether that convenience translates into commercial availability depends entirely on the Phase 3 pipeline, which had not produced published results as of this writing.

Phase 1 trials confirmed the compound's safety and tolerability in healthy volunteers. The Phase 2 trial was a randomized, double-blind, placebo-controlled study in women with HSDD. Participants in the Orenetide arm showed improvements in sexual desire, overall sexual function, and reduced distress scores compared to placebo. The full mechanism of action has not been detailed completely in publicly available sources, but it appears to act centrally, targeting brain pathways relevant to desire in a manner that the researchers and developers have positioned as distinct from both PT-141's melanocortin approach and Kisspeptin-10's hormonal mechanism.

The evidence here is early-stage clinical rather than established. Two phases of trial data exist and point in a positive direction, but Phase 3 confirmation has not been published, and Orenetide cannot be obtained through any standard prescribing channel. It appears in HSDD-focused research literature and in practitioner discussions tracking the development pipeline. Its presence on this list reflects that it is an active and serious candidate in the HSDD space, even though real-world use remains essentially nil outside of trial settings.

4. Oxytocin: For the Bonding and Arousal Component

Oxytocin is probably the most familiar compound on this list by name, often called the bonding hormone or the love hormone in popular coverage of social neuroscience. Its role in HSDD is narrower and more adjunctive than that reputation might suggest, which is why it appears fourth rather than earlier.

Oxytocin is a naturally occurring peptide produced in the hypothalamus and released by the pituitary gland. It plays a well-established role in social bonding, trust, and attachment, and it is physiologically involved in orgasm and arousal. The connection to HSDD is indirect: oxytocin does not drive the initiation of sexual desire the way PT-141's dopaminergic mechanism does. What it appears to support is the emotional intimacy and arousal components of sexual experience. That can be part of the broader picture for people whose low desire is entangled with difficulty feeling connected or emotionally present during sexual activity. There is also a mechanistic overlap worth noting: the melanocortin system that PT-141 activates modulates oxytocinergic pathways indirectly, suggesting that the two compounds are not operating in entirely separate physiological spaces.

The FDA has approved oxytocin as a prescription drug for obstetric indications, specifically labor induction and management of postpartum hemorrhage, at much higher doses and through intravenous delivery. For sexual health applications it is used off-label, typically as a compounded intranasal spray at far lower doses, available through some compounding pharmacies with a prescription.

The clinical evidence for oxytocin in HSDD specifically is mixed and limited. Small studies have pointed toward potential benefits for arousal and orgasm in both men and women. The data for desire itself, which is the core symptom of HSDD, is less convincing. No pivotal trial data exists for this application. The honest characterization is that oxytocin may have a complementary role, particularly for people whose sexual difficulty involves relational and arousal dimensions rather than pure desire initiation, but it is not a primary treatment for HSDD on the current evidence base.

In community discussions, oxytocin comes up most often as something used alongside PT-141 or other approaches rather than as a standalone therapy. The safety profile at low intranasal doses is generally considered favorable, informed partly by the compound's long clinical history in obstetric medicine, though the doses and routes are different enough that direct comparisons have real limits.

5. Melanotan II: Libido Effects With Significant Caveats

Melanotan II belongs on this list because it genuinely appears in conversations about HSDD and libido, and because understanding how it relates to PT-141 is useful context for anyone exploring this field. It also comes with more caveats than any other compound here, and those caveats are part of the honest picture.

Melanotan II is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide that activates the melanocortin receptor system. Unlike PT-141, which was developed specifically to improve selectivity, Melanotan II is a non-selective melanocortin agonist. It binds not just to MC4R, the primary desire-relevant receptor, but also to MC1R and MC3R. Activation of MC1R drives the tanning effect that gave Melanotan II its original name and its primary marketing presence. The libido and arousal effects come from the MC4R component of its action, the same receptor that PT-141 targets more precisely.

Studies have demonstrated pro-erectile effects and increased sexual desire with Melanotan II, and it was referenced in early research that helped establish the melanocortin system as a viable target for sexual dysfunction before PT-141 emerged as the more selective development candidate. In community discussions, people describe its libido effects as powerful, with reports of intense arousal and heightened desire. These accounts are real, but they come alongside a safety picture that is considerably less characterized than PT-141's and a regulatory status that offers no consumer protections.

Melanotan II has no FDA approval for any indication. It is not prescribed through telehealth platforms for sexual health and has no legitimate clinical pathway in the United States. It circulates as a research chemical, lacking the manufacturing quality controls, consistent potency verification, and clinical oversight that regulated products carry. The non-selective receptor binding means a broader range of off-target effects compared to PT-141, and the tanning effect is not merely cosmetic but a sign of broad melanocortin system activation. No comprehensive safety data from long-term human use has been published.

PT-141 was developed from Melanotan II precisely to improve selectivity and reduce off-target activity. For someone exploring peptides for HSDD, Melanotan II represents the less refined predecessor to the compound that earned FDA approval, and the gap between them in terms of clinical validation and regulatory oversight is substantial.

How These Peptides Compare

Frequently Asked Questions

Is PT-141 the same thing as Vyleesi?

PT-141 is the research name for bremelanotide, and Vyleesi is the FDA-approved brand name for the same compound. When someone receives a prescription through a telehealth platform or a physician, the regulated version they receive is Vyleesi. PT-141 also circulates as a compounded or research-chemical version through other channels, but those formulations are not FDA-approved and lack the manufacturing quality controls and clinical validation of the regulated product. The underlying peptide structure is the same; the regulatory status and manufacturing oversight differ significantly between the two forms.

Are any of these peptides approved for men with HSDD?

As of 2026, none of the peptides on this list carry FDA approval for HSDD or low sexual desire in men. PT-141 is approved only for premenopausal women with acquired, generalized HSDD. Off-label use in men is occurring through some telehealth platforms and compounding pharmacies, and Phase 2 trials studying PT-141 in men who had not responded to PDE5 inhibitors were underway as of 2025. Kisspeptin-10's 2023 Phase 2 trial included men and produced encouraging results, but it remains investigational. Anyone exploring peptide options for low desire as a man is working in off-label territory regardless of which compound they consider.

How is HSDD different from low libido in general?

The defining feature of HSDD is personal distress. Many people have lower-than-average sexual desire and are unbothered by it, which does not meet the diagnostic threshold for HSDD. The condition is specifically characterized by a persistent deficiency of sexual desire that causes marked distress to the person experiencing it or creates significant interpersonal difficulty. The distinction matters clinically because it defines who the formal research enrolled and who the FDA approved PT-141 for, which shapes how the evidence translates to individual situations.

How does PT-141 differ from sildenafil or other PDE5 inhibitors?

PT-141 works in the brain by activating melanocortin receptors that drive dopamine release in desire and motivation circuits, producing an increase in sexual wanting that originates centrally. PDE5 inhibitors like sildenafil work peripherally by relaxing blood vessel walls and increasing blood flow to genital tissue, facilitating the physical mechanics of arousal and erection without directly influencing the brain's desire signal. For people whose difficulty is specifically the absence of desire rather than a problem with physical function, the central mechanism is the more directly relevant one. The two compound classes are addressing different aspects of sexual response.

Can peptides substitute for addressing the root causes of low desire?

No, and people who use peptides for HSDD are consistent in noting this across community discussions. Chronic stress, relationship dynamics, sleep quality, hormonal status, and psychological factors all contribute to desire, and a peptide working centrally in the brain's desire circuits does not resolve those upstream conditions. The compounds on this list work best as part of a broader approach rather than as a workaround for unaddressed causes. This applies especially to oxytocin, which targets the relational and emotional dimension of sexual experience and has the least effect when non-physiological factors are working strongly against it.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for Hypoactive Sexual Desire Disorder (HSDD) in one place.